Ernexa Therapeutics ERNA Q3 2023 Earnings Net loss of 103 per share highlights ongoing clinical investment stock declines 377 HRB Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction Builders FirstSource BLDR Q1 2026 Earnings EPS Misses Estimates Amid Market Challenges PSTV Q1 2026 Earnings EPS Misses Estimates Amid Ongoing Clinical Development NEON Q1 2026 Earnings EPS Misses Estimates Amid Revenue Disclosure Gap ADMA Biologics Q1 2026 Earnings EPS Misses Estimates Amid Stock Downdraft